Robust immune responses elicited by a fully synthetic three-component vaccine. - Wikidata - wikimedia - TriplyDB

Robust immune responses elicited by a fully synthetic three-component vaccine.

Robust immune responses elicited by a fully synthetic three-component vaccine.

http://www.wikidata.org/entity/Q33721005

about

Vaccine adjuvants as potential cancer immunotherapeutics Synthetic self-adjuvanting glycopeptide cancer vaccines Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification Glycotherapy: new advances inspire a reemergence of glycans in medicine A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity Synthetic Nanoparticles for Vaccines and Immunotherapy Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening.Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc.Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Antibody recognition of fluorinated MUC1 glycopeptide antigens.Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model.Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy.Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.Cancer vaccines and carbohydrate epitopes.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Intact reducing glycan promotes the specific immune response to lacto-N-neotetraose-BSA neoglycoconjugates.A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity.Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model.Effects of hapten density on the induced antibody repertoire A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.Scalable synthesis of Fmoc-protected GalNAc-threonine amino acid and T(N) antigen via nickel catalysis.A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Clustered carbohydrates in synthetic vaccines.Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.Glycan antagonists and inhibitors: a fount for drug discovery.Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma.Carbohydrates and T cells: a sweet twosome.Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic

P2860

Q26752522-E5940514-0D7A-48EF-8342-5F3F7448DD7F Q26777837-EE00D1B8-8D52-434A-BEA7-708437D6BCDD Q27001592-9608DE7B-D115-45DE-8136-AEC68ACA7057 Q27027997-B7030E28-5496-4036-A6F3-C95195CFC84C Q27664589-5FE74DBF-D2A5-4018-A35C-C8AC5E03E8A3 Q28085375-2B75B818-BFD6-4F09-B39A-71760615080D Q29248835-7D73ABE9-F953-42D2-8AA1-728772D194EF Q33431143-F0A19D3A-E72F-4C04-82F3-160A469EDCEF Q33466255-5F511904-3A18-46C4-8289-2C8572DA9424 Q33489506-9C3855AC-337F-4435-9B0A-38BC82CE25DB Q33588328-B9372778-01EA-46EA-A3C8-8444880C0D76 Q33591916-B51DF7CE-D900-44B7-AEDA-D9CC4EA44CE9 Q33614657-546D0220-1157-4DE8-B33E-5FFD760BF8D3 Q33714195-43D511CD-E28C-480F-BDA9-3218CD679714 Q33802435-F972066F-FB36-4869-8946-396DBB0545E8 Q33961477-395DFCFC-4651-4742-B5CF-5EF308D1B928 Q34045866-BF4B5E4D-E713-49FB-A11F-C10967BF90AD Q34345467-04772492-47D5-407F-ADCD-CF43672CD5D5 Q34901076-02A926B5-826E-4772-8332-F25428B570B4 Q35030845-0C80DD25-351F-4C41-ACAF-AD5E80CF2E31 Q35525289-3014F50C-D2AA-47D2-A26D-56CF390009DD Q35657628-954123A6-C4E0-4FD4-9B74-D39319292F16 Q35753059-86F1EF82-A013-4373-A9F6-7B4EC3445FB8 Q35800918-E37CC1D3-4E08-4CFE-A180-6D49383F1B0E Q35854131-56C45E52-CADA-4296-816D-9D8311B2437B Q35897201-FDB322EA-7010-4482-B42A-598E53EDF2D6 Q36042286-75686C8E-7055-4824-82EA-EC813D6E6012 Q36200540-9C813C27-34BF-44E8-A3B3-2E591C1C983F Q36202229-36C4677B-D967-4E55-87D5-9629AF3FDDCE Q36292042-ECE04DA3-F00C-49CA-A2F8-46AC2853D8CD Q36351293-7BF7BFDE-7ECA-4902-BFD4-F6AA763EB91B Q36576120-16FCCCBA-2267-4471-A91A-5ABCB1AC272B Q36604334-2FF8E231-79C5-4871-BFBF-CDC80D441A86 Q36844110-72EC729F-3F4B-4810-86C0-82D3DFF56272 Q36869958-4205AD58-1746-4836-8867-4DF9FE3C9E35 Q37027396-DAD90B6E-2C4F-4197-86AF-29817241A762 Q37100578-6EA18104-C0C8-46AE-BDD2-5BBEFAD83750 Q37118132-40901611-2C51-47CE-976C-2D8076398675 Q37186518-C38319A6-8D95-4C1F-9F9B-20E46444A37F Q37303845-16D8D669-42E8-49B8-B666-993A347BD4B3

P2860

Robust immune responses elicited by a fully synthetic three-component vaccine.

http://www.wikidata.org/entity/Q33721005

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Robust immune responses elicited by a fully synthetic three-component vaccine.

@ast

Robust immune responses elicited by a fully synthetic three-component vaccine.

@en

type

label

Robust immune responses elicited by a fully synthetic three-component vaccine.

@ast

Robust immune responses elicited by a fully synthetic three-component vaccine.

@en

prefLabel

Robust immune responses elicited by a fully synthetic three-component vaccine.

@ast

Robust immune responses elicited by a fully synthetic three-component vaccine.

@en

P1433

Q33721005-52151590-5F5A-4239-9A3F-618125A66188

P1476

Q33721005-B67A0B8F-802F-4C74-9473-08D3ABFCA5F2

P2093

Q33721005-49BDCBD1-C199-4C2D-B4F2-144BDDBBE0B5

Q33721005-4C166182-1544-45A0-AB28-829B4595AF13

Q33721005-6E7873E0-4CEE-41E5-B54D-3D5E0F6948E1

P2860

Q33721005-00E679F3-E48A-4434-8D83-1B0FB6643A35

Q33721005-2461B8D1-87DA-46DC-BBB1-7AD726296B41

Q33721005-2846AE46-882F-4A7F-95AC-8F5F2175A0B7

Q33721005-40AF0AA7-88C9-47A2-A981-6363789F5B05

Q33721005-4696BA3F-148B-4971-80D1-D00FE477A688

Q33721005-50A07E1B-211C-4701-97C1-C17E9E41673C

Q33721005-5171C3F3-FBC8-41DF-825F-12DBB1A1A6B4

Q33721005-53E08437-AC5A-4C54-B08F-7774797FACB5

Q33721005-567B8AED-7B5F-431C-9F27-82FE6E40ADF8

Q33721005-577AA577-10F5-45F3-8238-C313A78F9CA1

P2888

Q33721005-8692C964-B9D7-4071-A573-85CE4D973D00

P304

Q33721005-DE18DB66-FDEE-48E8-A554-26860171D0F8

P31

Q33721005-A6B62856-0C3E-4621-AD18-53A9F50D8968

P356

Q33721005-F20041A2-C360-4B99-BEE5-F2835BB65B47

P433

Q33721005-D17980BE-944D-4B32-AC5B-C65FBFA68347

P478

Q33721005-713691BD-CC78-4EF9-A99A-4BCB5D74B444

P50

Q33721005-5E09C681-CCB2-4897-8EDC-ADBA6FC841EC

Q33721005-9EFD1645-F818-417E-8697-26BB24C2F505

P577

Q33721005-61D26D01-F00A-4B8C-BD2D-12245BF975D1

P5875

Q33721005-5416EA50-3373-4EA2-A992-8A2AB988AE4A

P698

Q33721005-01923713-04B0-440F-9735-F383FB286C93

P932

Q33721005-7FD510E1-E02A-4147-9EF7-5153D26D7224

P356

NCHEMBIO.2007.25

P1433

Nature Chemical Biology

P1476

Robust immune responses elicited by a fully synthetic three-component vaccine.

@en

P2093

Jidnyasa Gaekwad

http://www.w3.org/2001/XMLSchema#string

Sampat Ingale

http://www.w3.org/2001/XMLSchema#string

Therese Buskas

http://www.w3.org/2001/XMLSchema#string

P2860

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.

Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice

Toll-like receptors and T-helper-1/T-helper-2 responses.

Synthetic vaccines: the role of adjuvants in immune targeting.

Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

MUC1 and the MUCs: a family of human mucins with impact in cancer biology.

Glycans in cancer and inflammation--potential for therapeutics and diagnostics.

Carbohydrate vaccines as immunotherapy for cancer.

Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.

P2888

nchembio.2007.25

P304

663-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.2007.25

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Geert-Jan Boons

Margreet A Wolfert

P577

2007-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6073612

http://www.w3.org/2001/XMLSchema#string

P698

17767155

http://www.w3.org/2001/XMLSchema#string

P932

2836923

http://www.w3.org/2001/XMLSchema#string